ORCID Profile
0000-0003-4338-2662
Current Organisation
Pfizer
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Hindawi Limited
Date: 18-10-2018
DOI: 10.1155/2018/8245319
Publisher: Walter de Gruyter GmbH
Date: 06-2014
DOI: 10.2478/S11536-013-0286-Y
Abstract: Objective: To identify the viewpoints and perceptions of different stakeholders regarding high cost medicines (HCMs). Methods: A systematic review of the literature was performed to identify original research articles. Using predefined categories, data related to the viewpoints of different stakeholders was systematically extracted and analyzed. Results: Thirty seven original research articles matched the criteria. The main stakeholders identified include physicians, patients, public and health funding authorities. The influence of media and other economic and ethical issues were also identified in the literature. A large number of stakeholders were concerned about lack of access to HCMs. Physicians have difficulty balancing the the rational use of expensive drugs while at the same time acting as “patients’ advocate”. Patients would like to know about all treatment options, even if they may not be able to afford them. The process and criteria for reimbursement should be transparent and access has to be equitable across patient groups. Conclusion: Access to HCMs could be improved through transparency and involvement of all stakeholders, especially patients and the public. Moral issues and the “rule of rescue” could influence decision-making process significantly. At system level, objectivity is important to ensure that the system is equitable and transparent.
Publisher: Elsevier BV
Date: 02-2023
DOI: 10.1016/J.JAAD.2022.11.005
Abstract: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. To evaluate the efficacy and safety of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with active nonsegmental vitiligo (NSV) in a phase 2b trial (NCT03715829). Patients were randomized to once-daily oral ritlecitinib ± 4-week loading dose (200/50 mg, 100/50 mg, 30 mg, or 10 mg) or placebo for 24 weeks (dose-ranging period). Patients subsequently received ritlecitinib 200/50 mg daily in a 24-week extension period. The primary efficacy endpoint was percent change from baseline (%CFB) in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24. 364 patients were treated in the dose-ranging period. Significant differences from placebo in %CFB in F-VASI were observed for the ritlecitinib 50 mg groups with (-21.2 vs 2.1, P<0.001) or without (-18.5 vs 2.1, P<0.001) a loading dose and ritlecitinib 30 mg group (-14.6 vs 2.1, P=0.01). Accelerated improvement was observed after treatment with ritlecitinib 200/50 mg in the extension period (n=187). No dose-dependent trends in treatment-emergent or serious adverse events were observed across the 48-week treatment. Patients with stable vitiligo only were excluded. Oral ritlecitinib was effective and well-tolerated over 48 weeks in patients with active NSV.
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 07-2016
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 04-2015
Publisher: Springer International Publishing
Date: 2018
Publisher: Elsevier BV
Date: 02-2019
No related grants have been discovered for Yuji Yamaguchi.